Experimental vaccine combo takes on tough pancreatic cancer
NCT ID NCT07637786
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new peptide nanovaccine (ONVAX-01) together with an anti-PD-1 antibody and standard chemotherapy in 9 people with advanced pancreatic cancer that has worsened after prior treatment. The main goals are to see if the combination is safe and whether it can shrink tumors or stop the cancer from growing. Participants receive the vaccine as a shot under the skin and the other drugs through an IV, along with regular checkups and scans.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
peptide nanovaccine (ONVAX-01) plus an anti-PD-1 antibody and chemotherapy
What this could lead to
If it works, this could point toward a new combination treatment that shrinks tumors or slows disease progression in advanced pancreatic cancer.
What could go wrong
This is a very early phase 1 trial with only 9 participants, so results may not apply broadly. The combination may cause significant side effects or fail to show benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital of Sichuan University
Chengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••